Journal Mobile Options
Table of Contents
Vol. 27, Suppl. 1, 2009
Issue release date: April 2009

Relevance of Stroke Code, Stroke Unit and Stroke Networks in Organization of Acute Stroke Care – The Madrid Acute Stroke Care Program

Alonso de Leciñana-Cases M. · Gil-Núñez A. · Díez-Tejedor E.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Stroke is a neurological emergency. The early administration of specific treatment improves the prognosis of the patients. Emergency care systems with early warning for the hospital regarding patients who are candidates for this treatment (stroke code) increases the number of patients treated. Currently, reperfusion via thrombolysis for ischemic stroke and attention in stroke units are the bases of treatment. Healthcare professionals and health provision authorities need to work together to organize systems that ensure continuous quality care for the patients during the whole process of their disease. To implement this, there needs to be an appropriate analysis of the requirements and resources with the objective of their adjustment for efficient use. It is necessary to provide adequate information and continuous training for all professionals who are involved in stroke care, including primary care physicians, extrahospital emergency teams and all physicians involved in the care of stroke patients within the hospital. The neurologist has the function of coordinating the protocols of intrahospital care. These organizational plans should also take into account the process beyond the acute phase, to ensure the appropriate application of measures of secondary prevention, rehabilitation, and chronic care of the patients that remain in a dependent state. We describe here the stroke care program in the Community of Madrid (Spain).



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Bejot Y, Benatru I, Rouaud O, Fromont A, Besancenot JP, Moreau T, Giroud M: Epidemiology of stroke in Europe: geographic and environmental differences. J Neurol Sci 2007;262:85–88.
  2. Centers for Disease Control and Prevention (CDC): Prevalence of stroke – United States, 2005. MMWR Morb Mortal Wkly Rep 2007;56:469–474.

    External Resources

  3. Pan-American Health Organization: Regional Core Health Data Initiative. Available at www.paho.org/english/dd/ais/coredata.htm.
  4. Camargo EC, Bacheschi LA, Massaro AR: Stroke in Latin America. Neuroimaging Clin N Am 2005;15:283–296.
  5. Medrano Alberto MJ, Boix Martínez R, Cerrato Crespán E, Ramírez Santa-Pau M: Incidence and prevalence of ischaemic heart disease and cerebrovascular disease in Spain: a systematic review of the literature. Rev Esp Salud Publica 2006;80:5–15.

    External Resources

  6. Díaz Guzman J, Egido J, Abilleira S, Barberá G, Gabriel R en representación del Grupo Proyecto Ictus (GEECV) de la Sociedad Española de Neurología: Incidencia del ictus en España. Datos preliminares crudos del estudio IBERICTUS. Neurología 2007;22:605.
  7. Instituto Nacional de Estadística: Defunciones según la causa de muerte. Encuesta de morbilidad hospitalaria. Available at http://www.ine.es.
  8. Gresham GE, Kelly-Hayes M, Wolf PA, et al: Survival and functional status 20 or more years after stroke: the Framingham Study. Stroke 1998;29:793–797.
  9. Flynn RW, Macwalter RS, Doney AS: The cost of cerebral ischaemia. Neuropharmacology 2008;55:250–256.
  10. Beguiristain JM, Mar J, Aráosla A: Coste de la enfermedad cerebrovascular aguda. Rev Neurol 2005;40:406–411.
  11. Carod Artal FJ, Egido Herrero JA, Gonzalez Gutierrez JL, Varela de Seijas E: Coste directo de la enfermedad cerebrovascular en el primer año de seguimiento. Rev Neurol 1999;28:1123–1130.
  12. Hacke W, Donan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators: Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS and NINDS rt-PA stroke trials. Lancet 2004;363:768–774.
  13. Dávalos A, Castillo J, Martinez-Vila E: Delay in neurological attention and stroke outcome. Cerebrovascular Diseases Study Group of the Spanish Society of Neurology. Stroke 1995;26:2233–2237.
  14. Siesjö BK: Pathophysiology and treatment of focal cerebral ischemia. I. Pathophysiology. J Neurosurg 1992;77:169–184.

    External Resources

  15. Siesjö BK: Pathophysiology and treatment of focal cerebral ischemia. II. Mechanisms of damage and treatment. J Neurosurg 1992;77:337–354.
  16. García JH, Liu KF, Ho KL: Neuronal necrosis after middle cerebral artery occlusion in Wistar rats progresses at different time intervals in the caudoputamen and the cortex. Stroke 1995;26:636–643.
  17. Ferrer I: Apoptosis: future targets for neuroprotective strategies. Cerebrovasc Dis 2006;21(suppl 2):9–20.
  18. Castellanos M, Sobrino T, Castillo J: Evolving paradigms for neuroprotection: molecular identification of ischemic penumbra. Cerebrovasc Dis 2006;21(suppl 2):71–79.
  19. Lizasoain I, Cárdenas A, Hurtado O, Romera C, Mallolas J, Lorenzo P, Castillo J, Moro MA: Tragets of cytoprotection in acute ischemic stroke: present and future. Cerebrovasc Dis 2006;21(suppl 2):1–8.
  20. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF; American Heart Association; American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007;38:1655–1711.
  21. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med1995;333:1581–1587.
  22. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grand M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G; SITS-MOST Investigators: Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275–282.
  23. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators: Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-1329.
  24. Wahlgren N, Ahmed N, Dávalos A, Hacke W, Millán M, Muir K, Roine RO, Toni D, Lees KR; SITS Investigators: Thrombolysis with alteplase 3–4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008;372:1303–1309.
  25. Mar J, Begiristain JM, Arrazola A: Cost-effectiveness analysis of thrombolytic treatment for stroke. Cerebrovasc Dis 2005;20:193–200.
  26. Grotta J, Burgin S, El-Mitwalli A, Long M, Campbell M, Morgenstern LB, Malkoff M, Alexandrov AV: Intravenous tissue-type plasminogen activator therapy for ischemic stroke. Houston experience 1996–2000. Arch Neurol 2001;58:2009–2013.
  27. Cocho D, Belvís R, Martí-Fàbregas J, Molina-Porcel L, Díaz-Manera J, Aleu A, Pagonabarraga J, García-Bargo D, Mauri A, Martí-Vilalta JL: Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology 2005;64:719–720.
  28. Govan L, Langhorne P, Weir CJ; Stroke Unit Trialists Collaboration: Does the prevention of complications explain the survival benefit of organized inpatient (stroke unit) care? Further analysis of a systematic review. Stroke 2007;38:2536–2540.
  29. Díez-Tejedor E, Fuentes B: Homeostasis as basis of acute stroke treatment: stroke units are the key. Cerebrovasc Dis 2005;20(suppl 2):129–134.
  30. Seenan P, Long M, Langhorne P: Stroke units in their natural habitat: systematic review of observational studies. Stroke 2007;38:1886–1892.
  31. Fuentes B, Diez-Tejedor E, Ortega-Casarrubios MA, Martinez P, Lara M, Frank A: Consistency of the benefits of stroke units over years of operation: an 8-year effectiveness analysis. Cerebrovasc Dis 2006;21:173–179.
  32. Gil Núñez A, Vivancos Mora J: Organization of medical care in acute stroke. The importance of a good network. Cerebrovasc Dis 2004;17(suppl 1):113–123.

    External Resources

  33. Leys D, Ringelstein EB, Kaste M, Hacke W; Executive Committee of the European Stroke Initiative: Facilities available in European hospitals treating stroke patients. Stroke 2007;38:2985–2991.
  34. Segura T, Vega G, López S, Rubio F, Castillo J: Public perception of stroke in Spain. Cerebrovasc Dis 2003;16:21–26.
  35. Becker K, Fruin M, Gooding T, Tirschwell D, Love P, Mankowski T: Community-based education improves stroke knowledge. Cerebrovasc Dis 2001;11:34–43.
  36. Belvis R, Cocho D, Martí-Fábregas J, Pagonabarraga J, Aleu A, García-Bargo MD, et al: Benefits of a prehospital stroke code system. Feasibility and efficacy in the first year clinical practice in Barcelona, Spain. Cerebrovasc Dis 2005;19:96–101.
  37. Álvarez-Sabín J, Molina CA, Abilleira S, Montáner J, García Alfranca F, Jiménez-Fabrega X, et al: Impacto del código ictus en la eficacia del tratamiento trombolítico. Med Clin (Barc) 2003;120:47–51.
  38. Gómez CR, Malkoff MD, Sauer CM, Tulyapronchote R, Burch CM, Banet GA: Code Stroke. An attempt to shorten inhospital therapeutic delays. Stroke 1994;25:1920–1923.
  39. Zarza B, Alonso de Leciñana M, García-Barragán N, Díaz-Sánchez M, López-Sendón J, Cruz-Culebras A, Masjuán J: Influence of the experience and of out-of-hospital stroke code in thrombolytic treatment of acute stroke. Neurologia 2008;23:349–355.
  40. Organización de la asistencia en fase aguda del ictus: Unidades de ictus. Recomendaciones 2003 del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología. Gil Núñez A (coordinador). Madrid, EMISA, 2003.
  41. Stroke Unit Trialists’ Collaboration: Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev 2007;4:CD000197.
  42. Díez-Tejedor E, Fuentes B: Acute care in stroke: do stroke units make the difference? Cerebrovasc Dis 2001;11(suppl 1):31–39.
  43. Gilligan AK, Thrift AG, Sturm JW, Dewey HM, Macdonell RAL, Donan GA: Stroke units, tissue plasminogen activator, and neuroprotection: which stroke intervention could provide the greatest community benefit? Cerebrovasc Dis 2005;20:239–244.
  44. Fuentes B, Díez Tejedor E: Unidades de ictus. Una necesidad asistencial coste-efectiva. Neurología 2007;22:456–466.
  45. Kalra L, Evans A, Perez I, Knapp M, Donaldson N, Swift CG: Alternative strategies for stroke care: a prospective randomised controlled study of stroke unit, stroke team and domiciliary management of stroke. Lancet 2000;356:894–899.
  46. Alvarez Sabín J, Alonso de Leciñana M, Gállego J, Gil-Peralta A, Casado I, Castillo J, Díez Tejedor E, Gil A, Jiménez C, Lago A, Martínez-Vila E, Ortega A, Rebollo M, Rubio F; Grupo de Estudio de las Enfermedades Cerebrovasculares de la Sociedad Española de Neurología: Plan for stroke healthcare delivery. Neurologia 2006;21:717–726.

    External Resources

  47. Aboderin I, Venables G, Asplund K: Stroke management in Europe. J Intern Med 1996;240:173–180.
  48. Kjellström T, Norrving B, Shatchkute A: Helsingborg Declaration 2006 on European stroke strategies. Cerebrovasc Dis 2007;23:231–241.

    External Resources

  49. Canadian Stroke Network and the Heart and Stroke Foundation of Canada: Canadian Stroke Strategy. Canadian Best Practice Recommendations for Stroke Care. Ottawa, Canadian Stroke Network, 2006.
  50. Alberta Stroke Council: Alberta provincial stroke strategy. Improving stroke care-making a difference. Alberta, March 26, 2007; available at www.strokestrategy.ab.ca.
  51. Department of Health: Vascular Program. Stroke Team. A new ambition for stroke: a consultation on a national strategy. London, July 2007; available at www.dh.gov.uk/stroke.
  52. Díez Tejedor E, Fuentes B, Rodriguez-Balo A, Alonso de Leciñana M, Egido J, Gil-Nuñez A, Sánchez C, Vivancos J, Matías-Guiu J, Soria MA: Advantages of a Special Stroke Assistance Network. Madrid Acute Stroke Program. Cerebrovasc Dis 2008;25(suppl 2): 189.
  53. Gil Núñez A: Análisis y estrategia organizativa de la atención neurológica del ictus agudo en la Comunidad de Madrid; tesis doctoral. Madrid, Universidad Autónoma de Madrid, 2008.
  54. Vivancos J, Gil Núñez A (Coordinadores): Samur-Protección Civil. Servicio de Urgencias Médicas de Madrid-SUMMA 112 – Sociedad Española de Medicina de Urgencias y Emergencias, Agrupación Madrid. Foro de Ictus de Madrid, Asociación Madrileña de Neurología (Comité de redacción). Protocolo de Consenso para la Atención al Ictus en Fase Aguda en la Comunidad de Madrid. Madrid, Ferrer Internacional, 2006.
  55. Díez Tejedor E, Egido Herrero JA, Gil Núñez A, Matías Guiu Guía J, Alonso de Leciñana M, Sánchez Sánchez C, Vivancos Mora J, Soria Milla MA, Rodríguez Balo A: En nombre del Foro de Ictus de la Asociación Madrileña de Neurología, y la Dirección General del Servicio Madrileño de Salud – Subdirección General de Atención Especializada. Plan Asistencial del Ictus en la Comunidad de Madrid. Madrid, Consejería de Sanidad de la Comunidad de Madrid, 2008, in press.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50